{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T16:39:40Z","timestamp":1780677580708,"version":"3.54.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006209","name":"Radboud Universitair Medisch Centrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006209","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010806","name":"Amgen BV","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010806","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jacl.2022.10.006","type":"journal-article","created":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T20:14:02Z","timestamp":1667074442000},"page":"112-123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Effect of evolocumab on fasting and post fat load lipids and lipoproteins in familial dysbetalipoproteinemia"],"prefix":"10.1016","volume":"17","author":[{"given":"Britt E.","family":"Heidemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1487-1635","authenticated-orcid":false,"given":"Charlotte","family":"Koopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6870-9962","authenticated-orcid":false,"given":"Jeanine E.","family":"Roeters van Lennep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik S.G.","family":"Stroes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9197-8124","authenticated-orcid":false,"given":"Niels P.","family":"Riksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0460-3645","authenticated-orcid":false,"given":"Monique T.","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie C. van Vark","family":"\u2013 van der Zee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9899-4634","authenticated-orcid":false,"given":"Dee M.","family":"Blackhurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5678-5714","authenticated-orcid":false,"given":"A. David","family":"Marais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3951-5223","authenticated-orcid":false,"given":"Frank L.J.","family":"Visseren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jacl.2022.10.006_bib0001","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/MED.0000000000000316","article-title":"Familial dysbetalipoproteinemia: an underdiagnosed lipid disorder","volume":"24","author":"Koopal","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"3","key":"10.1016\/j.jacl.2022.10.006_bib0002","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.298.3.299","article-title":"Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women","volume":"298","author":"Nordestgaard","year":"2007","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jacl.2022.10.006_bib0003","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1172\/JCI112926","article-title":"Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III, and type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil","volume":"79","author":"Weintraub","year":"1987","journal-title":"The Journal of clinical investigation"},{"issue":"1","key":"10.1016\/j.jacl.2022.10.006_bib0004","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.atherosclerosis.2015.02.046","article-title":"Vascular risk factors, vascular disease, lipids and lipid targets in patients with familial dysbetalipoproteinemia: a European cross-sectional study","volume":"240","author":"Koopal","year":"2015","journal-title":"Atherosclerosis"},{"issue":"7","key":"10.1016\/j.jacl.2022.10.006_bib0005","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jacc.2004.11.062","article-title":"Brinton EA. Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease","volume":"45","author":"Hopkins","year":"2005","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.jacl.2022.10.006_bib0006","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgac503","article-title":"Dysbetalipoproteinemia is associated with increased risk of coronary and peripheral vascular disease","author":"Paquette","year":"2022","journal-title":"The Journal of clinical endocrinology and metabolism"},{"issue":"1","key":"10.1016\/j.jacl.2022.10.006_bib0007","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1194\/jlr.D200013-JLR200","article-title":"Non-denaturing polyacrylamide gradient gel electrophoresis for the diagnosis of dysbetalipoproteinemia","volume":"44","author":"Blom","year":"2003","journal-title":"J Lipid Res"},{"issue":"11","key":"10.1016\/j.jacl.2022.10.006_bib0008","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/S0022-2275(20)32417-2","article-title":"Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes","volume":"40","author":"Mahley","year":"1999","journal-title":"J Lipid Res"},{"issue":"10","key":"10.1016\/j.jacl.2022.10.006_bib0009","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.005367","article-title":"Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia","volume":"6","author":"Toth","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"10.1016\/j.jacl.2022.10.006_bib0010","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006910","article-title":"Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 35 Randomized Controlled Trials","volume":"6","author":"Karatasakis","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"18","key":"10.1016\/j.jacl.2022.10.006_bib0011","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.jacl.2022.10.006_bib0012","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jacl.2022.10.006_bib0013","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1007\/s00125-019-4856-7","article-title":"Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study","volume":"62","author":"Rosenson","year":"2019","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.jacl.2022.10.006_bib0014","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/dom.13960","article-title":"A placebo-controlled proof-of-concept study of alirocumab on postprandial lipids and vascular elasticity in insulin-treated patients with type 2 diabetes mellitus","volume":"22","author":"Burggraaf","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.jacl.2022.10.006_bib0015","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jacl.2019.12.003","article-title":"Impact of proprotein convertase subtilisin\/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects","volume":"14","author":"Taskinen","year":"2020","journal-title":"J Clin Lipidol"},{"issue":"2","key":"10.1016\/j.jacl.2022.10.006_bib0016","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1161\/ATVBAHA.120.315446","article-title":"Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100- and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes","volume":"41","author":"Taskinen","year":"2021","journal-title":"Arteriosclerosis, thrombosis, and vascular biology"},{"issue":"5","key":"10.1016\/j.jacl.2022.10.006_bib0017","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1373\/clinchem.2004.047001","article-title":"Screening for dysbetalipoproteinemia by plasma cholesterol and apolipoprotein B concentrations","volume":"51","author":"Blom","year":"2005","journal-title":"Clinical chemistry"},{"issue":"11","key":"10.1016\/j.jacl.2022.10.006_bib0018","first-page":"892","article-title":"Dysbetalipoproteinaemia\u2013clinical and pathophysiological features","volume":"92","author":"Blom","year":"2002","journal-title":"S Afr Med J"},{"key":"10.1016\/j.jacl.2022.10.006_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2020.06.004","article-title":"A simplified diagnosis algorithm for dysbetalipoproteinemia","author":"Paquette","year":"2020","journal-title":"J Clin Lipidol"},{"issue":"7","key":"10.1016\/j.jacl.2022.10.006_bib0020","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s40262-017-0620-7","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor","volume":"57","author":"Kasichayanula","year":"2018","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"10.1016\/j.jacl.2022.10.006_bib0021","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1161\/01.ATV.12.11.1336","article-title":"Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state","volume":"12","author":"Patsch","year":"1992","journal-title":"Arterioscler Thromb"},{"issue":"9","key":"10.1016\/j.jacl.2022.10.006_bib0022","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI103182","article-title":"The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum","volume":"34","author":"Havel","year":"1955","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.jacl.2022.10.006_bib0023","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"European heart journal"},{"key":"10.1016\/j.jacl.2022.10.006_bib0024","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12916-015-0358-8","article-title":"Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials","volume":"13","author":"Zhang","year":"2015","journal-title":"BMC Med"},{"issue":"11","key":"10.1016\/j.jacl.2022.10.006_bib0025","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1194\/jlr.M076901","article-title":"Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized placebo-controlled crossover trial","volume":"58","author":"Koopal","year":"2017","journal-title":"J Lipid Res"},{"issue":"1","key":"10.1016\/j.jacl.2022.10.006_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.hco.0000200416.65370.a0","article-title":"Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute scientific statement","volume":"21","author":"Grundy","year":"2006","journal-title":"Curr Opin Cardiol"},{"issue":"9965","key":"10.1016\/j.jacl.2022.10.006_bib0027","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"TESLA Investigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jacl.2022.10.006_bib0028","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jacc.2020.05.027","article-title":"Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia: The ODYSSEY HoFH Trial","volume":"76","author":"Blom","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jacl.2022.10.006_bib0029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0265838","article-title":"Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia)","volume":"17","author":"Waldmann","year":"2022","journal-title":"PloS one"},{"issue":"18","key":"10.1016\/j.jacl.2022.10.006_bib0030","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1001\/jama.2008.621","article-title":"Nonfasting triglycerides and risk of ischemic stroke in the general population","volume":"300","author":"Freiberg","year":"2008","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.jacl.2022.10.006_bib0031","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jacl.2016.10.001","article-title":"Autosomal dominant familial dysbetalipoproteinemia: A pathophysiological framework and practical approach to diagnosis and therapy","volume":"11","author":"Koopal","year":"2017","journal-title":"J Clin Lipidol"},{"issue":"18","key":"10.1016\/j.jacl.2022.10.006_bib0032","doi-asserted-by":"crossref","first-page":"15747","DOI":"10.1074\/jbc.M110.217638","article-title":"Proteolytic processing of angiopoietin-like protein 4 by proprotein convertases modulates its inhibitory effects on lipoprotein lipase activity","volume":"286","author":"Lei","year":"2011","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.jacl.2022.10.006_bib0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-2275(20)33334-4","article-title":"Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E","volume":"40","author":"Mahley","year":"1999","journal-title":"Journal of Lipid Research"},{"issue":"4","key":"10.1016\/j.jacl.2022.10.006_bib0034","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1074\/jbc.M708098200","article-title":"The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2","volume":"283","author":"Poirier","year":"2008","journal-title":"J Biol Chem"},{"issue":"48","key":"10.1016\/j.jacl.2022.10.006_bib0035","doi-asserted-by":"crossref","first-page":"50630","DOI":"10.1074\/jbc.M410077200","article-title":"Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin\/kexin type 9a in mouse liver","volume":"279","author":"Park","year":"2004","journal-title":"J Biol Chem"},{"issue":"47","key":"10.1016\/j.jacl.2022.10.006_bib0036","doi-asserted-by":"crossref","first-page":"48865","DOI":"10.1074\/jbc.M409699200","article-title":"NARC-1\/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol","volume":"279","author":"Benjannet","year":"2004","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.jacl.2022.10.006_bib0037","doi-asserted-by":"crossref","first-page":"e64145","DOI":"10.1371\/journal.pone.0064145","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1)","volume":"8","author":"Canuel","year":"2013","journal-title":"PloS one"},{"key":"10.1016\/j.jacl.2022.10.006_bib0038","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.thromres.2022.03.021","article-title":"Pleiotropic effects of PCSK9-inhibition on hemostasis: Anti-PCSK9 reduce FVIII levels by enhancing LRP1 expression","volume":"213","author":"Paciullo","year":"2022","journal-title":"Thromb Res"},{"issue":"1","key":"10.1016\/j.jacl.2022.10.006_bib0039","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41467-017-00568-7","article-title":"Heparan sulfate proteoglycans present PCSK9 to the LDL receptor","volume":"8","author":"Gustafsen","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jacl.2022.10.006_bib0040","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehz746.0332","article-title":"Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials","author":"Guedeney","year":"2019","journal-title":"European heart journal"},{"issue":"18","key":"10.1016\/j.jacl.2022.10.006_bib0041","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","article-title":"Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial","volume":"311","author":"Robinson","year":"2014","journal-title":"Jama"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287422002914?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287422002914?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:38:47Z","timestamp":1761831527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287422002914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1933287422002914"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2022.10.006","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of evolocumab on fasting and post fat load lipids and lipoproteins in familial dysbetalipoproteinemia","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2022.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 National Lipid Association. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}